Weight ManagementAppetiteFat LossBody CompositionAppetite suppression and weight loss

RESEARCH REFERENCE

Cagrilintide

Long-acting amylin analog for appetite regulation and weight management (often studied with semaglutide as CagriSema).

Quick Reference

Dose: Titrate to 2.4 mg (up to 4.5 mg studied)
Frequency / schedule: Once weekly
Route: Subcutaneous
Timing: Consistent day of the week (evening often preferred)
Fasting: Not required, but evening dosing 2+ hours post-meal is common
Cycle: 26–68+ weeks or ongoing
Time off: Per response
Common vial strengths: 5 mg, 10 mg

How this works

Cagrilintide is a long-acting acylated amylin analog. It activates amylin receptors (primarily in the area postrema) to promote satiety, slow gastric emptying, and reduce food intake. Half-life supports once-weekly dosing. When combined with semaglutide (CagriSema), the dual mechanism produces greater weight loss than either agent alone.

Benefits + side effects

Potential Benefits

Meaningful weight reduction as monotherapy
Stronger results in combination with semaglutide

Side Effects

Gastrointestinal (nausea, etc.) — dose-dependent and reduced by slow titration
Injection-site reactions

Dosing / Protocol

Reference Protocol

Phase / week	Dose	Frequency	Timing	Notes
Titration	0.3–0.6 → 1.2 → 2.4 mg	Once weekly	Same day	Step every 2–4 weeks
Maintenance	2.4 mg	Once weekly	Same day	Most common target

Timing + Fasting Notes

Same day each week. Evening (e.g., 6–8 PM) is often preferred. Food does not strongly affect absorption.

Reconstitution

Common vial strengths5 mg, 10 mg

Approved preparation example
5 mg + 2 mL BAC → 2.5 mg/mL

Practical Reference

Storage: Lyophilized frozen/refrigerated; reconstituted refrigerated
Route / injection context: Subcutaneous
Bloodwork / markers: Weight, glucose, lipids
Common vial strengths: 5 mg, 10 mg
Cycle / time off: 26–68+ weeks or ongoing · Per response
Practical notes: Slow titration essential. Research use only.

References

Once-weekly cagrilintide for weight management in people with overweight and obesityThe Lancet · 2021 · DOI 10.1016/S0140-6736(21)01751-7

CLINICAL TRIAL

THE SIGNAL · SENT TWICE A MONTH

Stay ahead of the research without living on PubMed.

Peptide references, research worth knowing, new FEMETRIC tools, and meaningful testing updates. Twice a month. No daily emails.By subscribing, you agree to receive The Signal from FEMETRIC. Unsubscribe anytime.

Search Femetric